Methods of treating demyelinating disorders

An ephrin and active technology, applied in the field of multiple sclerosis, can solve problems affecting the repair process and other issues

Inactive Publication Date: 2007-08-15
AVENTIS PHARMA INC
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Additionally suggesting that interference with the EphB1 signaling pathway may allow migration of o

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods of treating demyelinating disorders
  • Methods of treating demyelinating disorders
  • Methods of treating demyelinating disorders

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0026] A series of EphB1 mRNA expression profiles were analyzed on various cell types to determine the tissues in which EphB1 mRNA was expressed and the relative expression levels.

[0027] EphB1 mRNA levels were found to be enriched in oligodendrocytes. Figure 1 is a bar graph depicting the relative expression levels of EphB1 mRNA in four cell types: mature oligodendrocytes ("OL"), oligodendrocyte progenitors ("OLP"), astrocytes, and small Glial cells. Measurement of EphB1 expression was performed using a real-time reverse transcriptase polymerase chain reaction (RT-PCR) assay. RT-PCR is a well-established fluorescence-based quantitative assay of steady-state mRNA levels in the art. In the RT-PCR assay, EphB1 mRNA was reverse transcribed and amplified using PCR. PCR was performed using probes containing a fluorophore and a quencher specially designed so that the fluorophore dissociates from its quencher in each round of amplification such that the level of fluorescence inc...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Methods of identifying and using compounds capable of treating demyelinating disorders such as multiple sclerosis by inhibiting EphB1-mediated cell repulsion of CNS and PNS glial cells (oligodendrocytes and Schwann cells and progenitor cells within these lineages).

Description

technical field [0001] The present invention relates to the field of treatment of multiple sclerosis, in particular by inhibiting EphB1-mediated cellular rejection of CNS and peripheral glial cells (oligodendrocytes and Schwann cells) and progenitor cells within these lineages. The field of sexual sclerosis. Background technique [0002] All documents cited are hereby incorporated by reference in their entirety. [0003] The erythropoietin-producing hepatocellular ("Eph") receptors are a family of receptor tyrosine kinases that contain an extracellular domain as well as an intracellular tyrosine kinase domain, the The extracellular domain has a unique cysteine-rich motif as well as two fibronectin type III motifs (Connor RJ and Pasquale EB (1995) Oncogene 11:2429-381995), the intracellular tyrosine kinase The domain is involved in signal transduction (Vindis et al., J Cell Biol. 2003 Aug 18;162(4):661-71). Eph receptors are involved in neurodevelopment and physiology and ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): G01N33/68
Inventor K・尚德罗斯J・梅里尔S・纳特森
Owner AVENTIS PHARMA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap